- Home
- ITOS vs TRDA Comparison
ITOS vs TRDA Comparison
Compare ITOS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- TRDA
- Stock Information
- Founded
- ITOS 2011
- TRDA 2016
- Country
- ITOS United States
- TRDA United States
- Employees
- ITOS N/A
- TRDA N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- ITOS Health Care
- TRDA Health Care
- Exchange
- ITOS Nasdaq
- TRDA Nasdaq
- Market Cap
- ITOS 270.7M
- TRDA 301.0M
- IPO Year
- ITOS 2020
- TRDA 2021
- Fundamental
- Price
- ITOS $9.99
- TRDA $7.12
- Analyst Decision
- ITOS Hold
- TRDA Strong Buy
- Analyst Count
- ITOS 6
- TRDA 3
- Target Price
- ITOS $10.60
- TRDA $25.67
- AVG Volume (30 Days)
- ITOS 1.8M
- TRDA 129.9K
- Earning Date
- ITOS 08-07-2025
- TRDA 08-12-2025
- Dividend Yield
- ITOS N/A
- TRDA N/A
- EPS Growth
- ITOS N/A
- TRDA N/A
- EPS
- ITOS N/A
- TRDA 0.61
- Revenue
- ITOS $35,000,000.00
- TRDA $172,220,000.00
- Revenue This Year
- ITOS N/A
- TRDA N/A
- Revenue Next Year
- ITOS N/A
- TRDA N/A
- P/E Ratio
- ITOS N/A
- TRDA $11.74
- Revenue Growth
- ITOS 177.89
- TRDA 5.74
- 52 Week Low
- ITOS $4.80
- TRDA $6.94
- 52 Week High
- ITOS $18.13
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- ITOS 65.96
- TRDA 36.18
- Support Level
- ITOS $9.93
- TRDA $6.94
- Resistance Level
- ITOS $10.21
- TRDA $8.49
- Average True Range (ATR)
- ITOS 0.18
- TRDA 0.42
- MACD
- ITOS -0.11
- TRDA -0.07
- Stochastic Oscillator
- ITOS 18.07
- TRDA 10.91
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.